The Utilization of Low Dose Naltrexone for Chronic Pain

被引:1
|
作者
Poliwoda, Salomon [1 ]
Noss, Bryant [2 ]
Truong, Gia Thinh D. [2 ]
Creech, Zachary A. [2 ]
Koushik, Sarang S. [3 ]
Urits, Ivan [4 ,5 ]
Viswanath, Omar [6 ,7 ,8 ]
机构
[1] Mt Sinai Med Ctr, Dept Anesthesiol, 4300 Alton Rd, Miami Beach, FL 33140 USA
[2] Creighton Univ, Sch Med Phoenix, Phoenix, AZ USA
[3] Creighton Univ, Valleywise Hlth Med Ctr, Dept Anesthesiol & Pain Med, Sch Med Phoenix, Phoenix, AZ USA
[4] Louisiana State Univ Hlth Shreveport, Dept Anesthesiol, Shreveport, LA USA
[5] Southcoast Hlth Pain Management, Southcoast Hlth Phys Grp, Wareham, MA USA
[6] Innovat Pain & Wellness, Scottsdale, AZ USA
[7] Louisiana State Univ, Dept Anesthesiol, Hlth Sci Ctr Shreveport, Shreveport, LA USA
[8] Creighton Univ, Dept Anesthesiol, Sch Med, Phoenix, AZ USA
关键词
CONTROLLED-TRIAL; CROHNS-DISEASE; PILOT TRIAL; FIBROMYALGIA; ANTAGONISTS; MANAGEMENT; SAFETY; METABOLISM; DEPENDENCE; ANALGESIA;
D O I
10.1007/s40263-023-01018-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Naltrexone is a mu-opioid receptor antagonist with a long half-life compared with naloxone. Both of these drugs, along with others, were developed with the intention of reversing the effects of opioid abuse or toxicity. Evidence has also shown that naltrexone has a benefit in preventing relapse by reducing opioid cravings and reducing symptoms of opioid withdrawal. The benefits of this drug were not only shown with opioid abuse. In 1984 this drug was also approved for alcohol abuse. Naltrexone has been proven to decrease alcohol relapse by decreasing the craving. Apart from these approved indications for the use of naltrexone, with time, it has been seen that this drug has a benefit in treating chronic pain. A number of studies have shown the benefits of this drug with inflammatory bowel disease, fibromyalgia, multiple sclerosis, diabetic neuropathy, and complex regional pain syndrome, among others. More studies are needed to approve this medication for specific chronic pain conditions.
引用
收藏
页码:663 / 670
页数:8
相关论文
共 50 条
  • [21] Comments on "Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review"
    Singh, Anjali
    Khuba, Sandeep
    Agarwal, Anil
    Gautam, Sujeet
    Kumar, Sanjay
    Shamshrey, Chetna
    PAIN PHYSICIAN, 2021, 24 (08) : E1307 - E1307
  • [22] Utilization of Low-Dose Naltrexone for Burning Mouth Syndrome: A Case Report
    Neuman, Daniel L.
    Chadwick, Andrea L.
    A & A PRACTICE, 2021, 15 (05) : e01475
  • [23] Low Dose Naltrexone (LDN): New in the treatment of chronic pain syndromes. What really matters - reduced pain or increased energy?
    Bendiksen, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E357 - E358
  • [24] Low Dose Naltrexone in Dermatology
    Jaros, Joanna
    Lio, Peter
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (03) : 235 - 238
  • [25] The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders
    Patten, Denise K.
    Schultz, Bob G.
    Berlau, Daniel J.
    PHARMACOTHERAPY, 2018, 38 (03): : 382 - 389
  • [26] Comments on "Low-Dose Naltrexone Use for Patients with Chronic Regional Pain Syndrome: A Systematic Literature Review" Response
    Soin, Amol
    Soin, Yasmeen
    Dann, Tammy
    Buenaventura, Ricardo
    Ferguson, Kris
    Atluri, Sairam
    Sachdeva, Harsh
    Sudarshan, Gururau
    Akbik, Humam
    Italiano, Jordan
    PAIN PHYSICIAN, 2021, 24 (08) : E1308 - E1308
  • [27] Ultra-low dose of naltrexone attenuates neuropathic but not acute pain in rats
    Hamann, SR
    Hatch, NW
    Hicks, DL
    Wala, EP
    FASEB JOURNAL, 2004, 18 (05): : A961 - A961
  • [28] Low dose naltrexone in refractory neuropathic pain associated with autoimmune transverse myelitis
    Dey, S.
    Alexander, G.
    Lopez, E. Aradillas
    JOURNAL OF PAIN, 2015, 16 (04): : S75 - S75
  • [29] Efficacy and Tolerability of Low-dose Naltrexone for Pain Relief among Neuropathic Corneal Pain Patients
    Dieckmann, Gabriela
    Ozmen, Mehmet Cuneyt
    Engert, Ryan
    Hamrah, Pedram
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [30] Chronic very low dose naltrexone administration attenuates opioid withdrawal expression
    Mannelli, P
    Gottheil, E
    Peoples, JF
    Oropeza, VC
    Van Bockstaele, EJ
    BIOLOGICAL PSYCHIATRY, 2004, 56 (04) : 261 - 268